Agomab Therapeutics vs MasterControl
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data for AGMB-447 in IPF. Gut-restricted ALK5 inhibitor.
About
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
MasterControl is the leading QMS and MES platform for regulated life sciences industries, serving 1,100+ companies with $200M revenue in 2025; valued at $1.3B after $150M from Sixth Street, acquired Qualer in Mar 2025.
About
MasterControl is a leading provider of quality management system (QMS) and manufacturing execution system (MES) software for regulated industries, with a primary focus on pharmaceuticals, medical devices, biotechnology, and food and beverage. The company's AI-powered platform digitizes and automates compliance-critical workflows including document control, training management, audit management, change control, corrective and preventive action (CAPA), risk management, and electronic batch records — replacing paper-based processes that are error-prone, audit-vulnerable, and incompatible with modern manufacturing velocity.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.